Migalastat Hydrochloride 123 mg Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 123 mg
Originator reference: Galafold (USA/EU) (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Orphan Drugs
Migalastat is an orally administered small molecule that acts as a “pharmacological chaperone” by binding and stabilizing the enzyme α-galactosidase A (α-Gal A) in patients with certain amenable mutations, thereby helping to clear the substrate accumulation seen in Fabry disease.
Manufacture or export Migalastat Hydrochloride? List it or send an offer →
Product Description:
Migalastat is a pharmacological chaperone, and its mechanism is unusual. In Fabry disease, mutations in the gene for alpha-galactosidase A often produce an enzyme that folds incorrectly and is destroyed by the cell's quality control before it reaches the lysosome — the protein is not absent, just misfolded. Migalastat binds the enzyme's active site and stabilises the folded shape, so it survives trafficking to the lysosome, where the acidic environment releases it and it works.
It is used for Fabry disease in patients aged twelve and over who have an amenable mutation — and that qualifier is central, because the chaperone only helps mutations that produce a rescuable protein. Roughly a third to a half of Fabry mutations are amenable, determined by a validated in vitro test, and patients without one gain nothing. For those who qualify it is an oral capsule taken every other day, against the fortnightly intravenous infusions that enzyme replacement therapy requires. Headache is the commonest adverse effect.
Sourcing notes. Originator product, on patent, no generic. Access depends on genotype testing and on a published amenability table, so the destination market needs that testing. Supply is through authorised distribution; the competition is enzyme replacement therapy, not another oral agent.
Migalastat Hydrochloride — third party manufacturing & bulk supply
Migalastat Hydrochloride 123 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Migalastat Hydrochloride is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Migalastat Hydrochloride listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Migalastat Hydrochloride →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Migalastat Hydrochloride is used for the long-term treatment of adults with Fabry disease, a rare genetic disorder caused by deficient activity of the enzyme alpha-galactosidase A. It helps stabilize and enhance the function of certain mutant forms of the enzyme, reducing the accumulation of harmful substances in the body.
Migalastat Hydrochloride is made from the active ingredient migalastat hydrochloride, an oral pharmacological chaperone that binds selectively to specific mutant forms of alpha-galactosidase A, allowing the enzyme to fold correctly and function more effectively.
Migalastat Hydrochloride is marketed under the trade name Galafold.
Migalastat Hydrochloride is manufactured by Amicus Therapeutics.
The generic name of Migalastat Hydrochloride is Migalastat Hydrochloride.
The brand name of Migalastat Hydrochloride is Galafold.
Migalastat Hydrochloride is manufactured in the United States and the European Union by Amicus Therapeutics and its contract manufacturing partners.
Related Products
Emapalumab-Lzsg
Strength:
10 mg/2 mL, 50 mg/10 mL
Form: Injection
Originator reference: Gamifant (USA/EU)
View DetailsAgalsidase Beta
Strength:
35 mg
Form: Injection
Originator reference: Fabrazyme (USA/EU)
View DetailsTaliglucerase Alfa
Strength:
200U
Form: Injection
Originator reference: Elelyso (USA/EU)
View DetailsDoxecitine + Doxribtimine
Strength:
2g+2g
Form: Oral Solution
Originator reference: Kygevvi (USA)
View DetailsIvacaftor Tablet
Strength:
150 mg
Form: Tablets
Originator reference: Kalydeco®(US & EU)
View DetailsLumacaftor + Ivacaftor Tablets
Strength:
200 mg lumacaftor + 125 mg ivacaftor
Form: Tablets
Originator reference: Orkambi®(US & EU)
View DetailsRomiplostim Injection
Strength:
250mcg/vial, 500 mcg/vial
Form: Injection
Originator reference: Nplate®(US & EU)
View DetailsBosentan Tablet
Strength:
62.5 mg and 125 mg
Form: Tablets
Originator reference: Tracleer®(US & EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit